Literature DB >> 22434243

Complete pathologic response after combined modality treatment for rectal cancer and long-term survival: a meta-analysis.

Luigi Zorcolo1, Alan S Rosman, Angelo Restivo, Michele Pisano, Giuseppe R Nigri, Alessandro Fancellu, Marcovalerio Melis.   

Abstract

BACKGROUND: Complete pathologic response (CPR) after neoadjuvant chemoradiotherapy (combined modality treatment, CMT) for rectal cancer seems associated with improved survival compared to partial or no response (NPR). However, previous reports have been limited by small sample size and single-institution design.
METHODS: A systematic literature review was conducted to detect studies comparing long-term results of patients with CPR and NPR after CMT for rectal cancer. Variables were pooled only if evaluated by 3 or more studies. Study end points included rates of CPR, local recurrence (LR), distant recurrence (DR), 5-year overall survival (OS), and disease-free survival (DFS).
RESULTS: Twelve studies (1,913 patients) with rectal cancer treated with CMT were included. CPR was observed in 300 patients (15.6%). CPR and NPR patient groups were similar with respect to age, sex, tumor size, distance of tumor from the anus, and stage of disease before treatment. Median follow-up ranged from 23 to 46 months. CPR patients had lower rates of LR [0.7% vs. 2.6%; odds ratio (OR) 0.45, 95% confidence interval (CI) 0.22-0.90, P = 0.03], DR (5.3% vs. 24.1%; OR 0.15, 95% CI 0.07-0.31, P = 0.0001), and simultaneous LR + DR (0.7% vs. 4.8%; OR 0.32, 95% CI 0.13-0.79, P = 0.01). OS was 92.9% for CPR versus 73.4% for NPR (OR 3.6, 95% CI 1.84-7.22, P = 0.002), and DFS was 86.9% versus 63.9% (OR 3.53, 95% CI 1.62-7.72, P = 0.002).
CONCLUSIONS: CPR after CMT for rectal cancer is associated with improved local and distal control as well as better OS and DFS.

Entities:  

Mesh:

Year:  2012        PMID: 22434243     DOI: 10.1245/s10434-011-2209-y

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  70 in total

1.  Rectal cancer patients after neoadjuvant radiotherapy (30Gy/10f) with negative lymph node may not benefit from postoperative adjuvant chemotherapy: a retrospective study.

Authors:  Pengju Chen; Yunfeng Yao; Jin Gu
Journal:  Int J Colorectal Dis       Date:  2015-08-18       Impact factor: 2.571

Review 2.  Neoadjuvant Treatment for Locally Advanced Rectal Cancer: New Concepts in Clinical Trial Design.

Authors:  Nitesh Rana; A Bapsi Chakravarthy; Lisa A Kachnic
Journal:  Curr Treat Options Oncol       Date:  2017-02

3.  Changing operative strategy from abdominoperineal resection to sphincter preservation in T3 low rectal cancer after downstaging by neoadjuvant chemoradiation: a preliminary report.

Authors:  Khaled M Madbouly; Ahmed M Hussein
Journal:  World J Surg       Date:  2015-05       Impact factor: 3.352

4.  Report from the 19th annual Western Canadian Gastrointestinal Cancer Consensus Conference; Winnipeg, Manitoba; 29-30 September 2017.

Authors:  C A Kim; S Ahmed; S Ahmed; B Brunet; H Chalchal; R Deobald; C Doll; M P Dupre; V Gordon; R M Lee-Ying; H Lim; D Liu; J M Loree; J P McGhie; K Mulder; J Park; B Yip; R P Wong; A Zaidi
Journal:  Curr Oncol       Date:  2018-08-14       Impact factor: 3.677

5.  Comparison of Capecitabine (Xeloda) vs. Combination of Capecitabine and Oxaliplatin (XELOX) as Neoadjuvant CRT for Locally Advanced Rectal Cancer.

Authors:  Ali Yaghobi Joybari; Payam Azadeh; Siamak Babaei; Farnaz Hosseini Kamal
Journal:  Pathol Oncol Res       Date:  2019-02-02       Impact factor: 3.201

6.  Interval between neoadjuvant treatment and definitive surgery in locally advanced rectal cancer: impact on response and oncologic outcomes.

Authors:  Felipe A Calvo; Virginia Morillo; Marcos Santos; Javier Serrano; Marina Gomez-Espí; Marcos Rodriguez; Emilio Del Vale; Jose Luis Gracia-Sabrido; Carlos Ferrer; Claudio Sole
Journal:  J Cancer Res Clin Oncol       Date:  2014-06-01       Impact factor: 4.553

7.  A Prospective Study of Distal Microscopic Spread in Rectal Cancer After Neoadjuvant Chemoradiation in Pinned and Unpinned Specimen.

Authors:  Aravind S Kapali; K Chandramohan; A V Jayasudha
Journal:  Indian J Surg Oncol       Date:  2017-03-18

8.  Retrospective analysis of pathological response in colorectal cancer liver metastases following treatment with bevacizumab.

Authors:  R Vera; M Gomez Dorronsoro; S Lopez-Ben; A Viudez; B Queralt; I Hernandez; M R Ortiz-Duran; C Zazpe; J Soriano; I Amat; J Herrera Cabezón; E Diaz; A Codina-Barreras; X Hernandez-Yagüe; A Quera; J Figueras
Journal:  Clin Transl Oncol       Date:  2013-12-12       Impact factor: 3.405

9.  Neoadjuvant chemo-radiotherapy for cT3N0 rectal cancer: any benefit over upfront surgery? A propensity score-matched study.

Authors:  Luca Sorrentino; Marcello Guaglio; Luigi Battaglia; Giuliano Bonfanti; Marco Vitellaro; Alessandro Cesa Bianchi; Massimo Milione; Filiberto Belli
Journal:  Int J Colorectal Dis       Date:  2019-11-18       Impact factor: 2.571

10.  Pathologic response grade after long-course neoadjuvant chemoradiation does not influence morbidity in locally advanced mid-low rectal cancer resected by laparoscopy.

Authors:  Filippo Landi; Eloy Espín; Victor Rodrigues; Francesc Vallribera; Aleix Martinez; Cecile Charpy; Francesco Brunetti; Daniel Azoulay; Nicola de'Angelis
Journal:  Int J Colorectal Dis       Date:  2016-10-19       Impact factor: 2.571

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.